None
Quote | BridgeBio Pharma Inc. (NYSE:BBIO)
Last: | $ |
---|---|
Change Percent: | -0.55% |
Open: | $35.05 |
Close: | $34.65 |
High: | $35.07 |
Low: | $33.77 |
Volume: | 249,717 |
Last Trade Date Time: | 02/12/2020 04:42:27 pm |
News | BridgeBio Pharma Inc. (NYSE:BBIO)
2024-06-25 14:07:48 ET More on iShares Russell 2000 ETF: IWM: Small Caps Look Unattractive With Deteriorating Earnings Outlook IWM: Favor Small Caps Over The Technology Sector IWM: Not The Economy For Underdogs (Rating Downgrade) Gap between growth and small-...
2024-06-25 06:45:00 ET Summary Alnylam has been extremely persistent over the years in getting their RNA interference ideas developed and tested. That original RNAi therapy (patisiran) was directed towards neuropathy, but Alnylam has been hoping that such treatments would show ben...
Message Board Posts | BridgeBio Pharma Inc. (NYSE:BBIO)
Subject | By | Source | When |
---|---|---|---|
Offering comign | Pt3 | investorshub | 03/06/2023 4:47:20 PM |
BridgeBio Announces Positive Phase 2 Cohort 5 Results | 02opida | investorshub | 03/06/2023 4:21:16 PM |
BridgeBio Announces Positive Phase 2 Cohort 5 Results | subslover | investorshub | 03/06/2023 1:34:59 PM |
Recent Trades - Last 10 of 1063 | 02opida | investorshub | 12/08/2022 4:21:10 PM |
volume will start to pickup | 02opida | investorshub | 08/09/2022 6:09:28 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that Neil Kumar, Ph.D., founder and CEO...